A Phase 2 interventional study of Placebo and Aliskiren 300 mg in Post Acute Coronary Syndrome and Myocardial Ischemia, sponsored by Novartis. Completed at 11 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 218 studies in Myocardial Ischemia with a site in United States — 23 open to participants now, 26 under way, none of them phase 3. Myocardial Ischemia · United States.
Among the 218 studies in Myocardial Ischemia with a site in United States, this one is the 31st largest by enrollment of the 150 interventional ones that give a count, is one of 8 that started in 2007, is one of 27 in phase 2, and was the 42nd registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →23 of the 218 studies in Myocardial Ischemia with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Medtronic Cardiac Ablation Solutions · Sites in United States
Ages 18–85
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
218 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 31 · Phase 3 21 · Phase 4 19
First in 1990; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,101 is above the median of 116 across 622 interventional studies indexed under Myocardial Ischemia.
Median enrollment 87 across the 150 interventional studies, 205 across the 67 observational. Of the 172 that completed or were terminated, 77 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 218 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Novartis has 2 studies filed under Myocardial Ischemia — fewer than ten, so there is no comparison to draw.
6 of the studies in Myocardial Ischemia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06703489Medtronic Cardiac Ablation SolutionsSafety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS) | 2026-11 |
| NCT06271577AliveCorSmartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II | 2026-12 |
| NCT02855554Medical University of South CarolinaQuantitative Cardiac Parametric Mapping | 2026-12 |
| NCT05788666NYU Langone HealthUse of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease | 2027-03-01 |
| NCT06047028University of Texas Southwestern Medical CenterPrognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 218 studies in Myocardial Ischemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular hemodynamics, as reflected by a greater reduction in levels of N-terminal proB-type natriuretic peptide (NT-proBNP) compared to placebo in subjects stabilized following acute coronary syndrome (ACS) who are determined to be at high risk due to an elevated concentration of natriuretic peptides.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo tablets and capsules
Drug: Placebo
Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
Drug: Aliskiren 300 mg
Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.
Drug: Valsartan 320 mg
Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
Drug: Aliskiren/valsartan 300/320 mg
Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 8
Blood samples for the measurement of NT-proBNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.
Time frame: Baseline to Week 8
Change From Baseline in B-type Natriuretic Peptide (BNP) at Week 8
Blood samples for the measurement of BNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.
Time frame: Baseline to Week 8
Percentage of Patients With a Cardiac Event
A cardiac event was defined as at least one of the following events: Cardiovascular death, recurrent myocardial infarction (MI), or hospitalization for congestive heart failure (CHF), all to be confirmed by adjudication.
Time frame: Baseline to Week 8
Percentage of Patients With a Composite Clinical-biochemical Event
A composite clinical-biochemical event was defined as at least one of the following events: cardiovascular death confirmed by adjudication, recurrent MI confirmed by adjudication, hospitalization for CHF confirmed by adjudication, and/or NT-proBNP =\> 200 pg/mL.
Time frame: Baseline to Week 8
| Milestone | Placebo | Aliskiren 300 mg | Valsartan 320 mg | Aliskiren/Valsartan 300/320 mg |
|---|---|---|---|---|
| Started | 280 | 271 | 269 | 281 |
| Completed | 228 | 201 | 215 | 214 |
| Not completed | 52 | 70 | 54 | 67 |
| Withdrew: Adverse event | 27 | 37 | 25 | 33 |
| Withdrew: Abnormal laboratory value(s) | 2 | 2 | 2 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 2 |
| Withdrew: Subject no longer requires study drug | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 8 | 15 | 16 | 17 |
| Withdrew: Lost to follow-up | 2 | 0 | 2 | 2 |
| Withdrew: Administrative problems | 8 | 9 | 2 | 4 |
| Withdrew: Death | 2 | 4 | 4 | 2 |
| Withdrew: Protocol violation | 3 | 2 | 3 | 1 |
| Withdrew: Missing | 0 | 1 | 0 | 1 |
Blood samples for the measurement of NT-proBNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.
| pg/mL | Placebo | Aliskiren 300 mg | Valsartan 320 mg | Aliskiren/Valsartan 300/320 mg |
|---|---|---|---|---|
| Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 8 | 0.582 (0.502 to 0.676) | 0.563 (0.483 to 0.656) | 0.614 (0.526 to 0.716) | 0.635 (0.548 to 0.737) |
Blood samples for the measurement of BNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.
| pg/mL | Placebo | Aliskiren 300 mg | Valsartan 320 mg | Aliskiren/Valsartan 300/320 mg |
|---|---|---|---|---|
| Change From Baseline in B-type Natriuretic Peptide (BNP) at Week 8 | 0.642 (0.535 to 0.770) | 0.597 (0.495 to 0.720) | 0.670 (0.554 to 0.810) | 0.682 (0.568 to 0.818) |
A cardiac event was defined as at least one of the following events: Cardiovascular death, recurrent myocardial infarction (MI), or hospitalization for congestive heart failure (CHF), all to be confirmed by adjudication.
| Percentage of patients | Placebo | Aliskiren 300 mg | Valsartan 320 mg | Aliskiren/Valsartan 300/320 mg |
|---|---|---|---|---|
| Percentage of Patients With a Cardiac Event | 2.9 | 4.9 | 4.9 | 4.0 |
A composite clinical-biochemical event was defined as at least one of the following events: cardiovascular death confirmed by adjudication, recurrent MI confirmed by adjudication, hospitalization for CHF confirmed by adjudication, and/or NT-proBNP =\> 200 pg/mL.
| Percentage of patients | Placebo | Aliskiren 300 mg | Valsartan 320 mg | Aliskiren/Valsartan 300/320 mg |
|---|---|---|---|---|
| Percentage of Patients With a Composite Clinical-biochemical Event | 79.5 | 73.5 | 77.2 | 75.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 26/278 (9.4%) | 64/278 (23%) |
| Aliskiren 300 mg | — | 39/264 (14.8%) | 61/264 (23.1%) |
| Valsartan 320 mg | — | 33/268 (12.3%) | 51/268 (19%) |
| Aliskiren/Valsartan 300/320 mg | — | 46/279 (16.5%) | 57/279 (20.4%) |
| Event | Placebo | Aliskiren 300 mg | Valsartan 320 mg | Aliskiren/Valsartan 300/320 mg |
|---|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 2/278 | 7/264 | 2/268 | 3/279 |
| Angina pectorisCardiac disorders | 2/278 | 5/264 | 3/268 | 6/279 |
| Myocardial infarctionCardiac disorders | 1/278 | 2/264 | 0/268 | 5/279 |
| Acute myocardial infarctionCardiac disorders | 1/278 | 4/264 | 2/268 | 0/279 |
| Angina unstableCardiac disorders | 1/278 | 2/264 | 1/268 | 4/279 |
| Myocardial ischaemiaCardiac disorders | 0/278 | 1/264 | 1/268 | 4/279 |
| Acute coronary syndromeCardiac disorders | 0/278 | 3/264 | 1/268 | 1/279 |
| HypotensionVascular disorders | 0/278 | 3/264 | 0/268 | 2/279 |
| Cardiac failureCardiac disorders | 2/278 | 1/264 | 3/268 | 2/279 |
| PneumoniaInfections and infestations | 1/278 | 0/264 | 3/268 | 1/279 |
| Event | Placebo | Aliskiren 300 mg | Valsartan 320 mg | Aliskiren/Valsartan 300/320 mg |
|---|---|---|---|---|
| DizzinessNervous system disorders | 15/278 | 23/264 | 13/268 | 19/279 |
| HeadacheNervous system disorders | 18/278 | 10/264 | 7/268 | 10/279 |
| HyperkalaemiaMetabolism and nutrition disorders | 17/278 | 16/264 | 13/268 | 13/279 |
| Orthostatic hypotensionVascular disorders | 14/278 | 16/264 | 12/268 | 13/279 |
| Angina pectorisCardiac disorders | 13/278 | 9/264 | 14/268 | 8/279 |
| Age Continuous(years) | Placebo | Aliskiren 300 mg | Valsartan 320 mg | Aliskiren/Valsartan 300/320 mg | Total |
|---|---|---|---|---|---|
| Mean | 63 ± 11.8 | 63 ± 11.7 | 64 ± 11.6 | 63 ± 11.1 | 63 ± 11.6 |
| Sex: Female, Male(Participants) | Placebo | Aliskiren 300 mg | Valsartan 320 mg | Aliskiren/Valsartan 300/320 mg | Total |
|---|---|---|---|---|---|
| Female | 103 | 86 | 72 | 87 | 348 |
| Male | 177 | 185 | 197 | 194 | 753 |
The record gives a start of Feb 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aliskiren · Valsartan